Recent Quotes (30 days)

You have no recent quotes
chg | %

Cardiome Pharma Corp  

(Public, TSE:COM)   Watch this stock  
Find more results for COM
12.31
+0.46 (3.88%)
Aug 4 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 11.89 - 12.40
52 week 6.62 - 13.80
Open 11.89
Vol / Avg. 6,150.00/2,678.00
Mkt cap 208.89M
P/E     -
Div/yield     -
EPS -1.51
Shares 16.77M
Beta 1.09
Inst. own     -
Aug 12, 2015
Cardiome Pharma Corp at Canaccord Genuity Growth Conference - 11:30AM EDT - Add to calendar
Aug 5, 2015
Q2 2015 Cardiome Pharma Corp Earnings Call - 8:00AM EDT - Add to calendar
Aug 5, 2015
Q2 2015 Cardiome Pharma Corp Earnings Release Add to calendar
Jun 16, 2015
Cardiome Pharma Corp Annual Shareholders Meeting (Estimated)
May 13, 2015
Q1 2015 Cardiome Pharma Corp Earnings Call
May 13, 2015
Q1 2015 Cardiome Pharma Corp Earnings Release
  

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -70.71% -60.67%
Operating margin -48.34% -55.21%
EBITD margin - -48.05%
Return on average assets -33.61% -37.41%
Return on average equity -99.95% -91.63%
Employees 85 -
CDP Score - -

Address

1441 Creekside Dr 6th Floor
VANCOUVER, BC V6J 4S7
Canada
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

Description

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is focused on the development and commercialization of cardiovascular therapies that improve the life and health of patients suffering from heart disease. The Company has two marketed, in-hospital, cardiology products, BRINAVESSTM and AGGRASTAT, which are commercially available in markets outside of the United States. BRINAVESSTM (vernakalant (IV)), is approved in the European Union, and is registered and approved in approximately 50 countries for the conversion of onset atrial fibrillation to sinus rhythm in adults (for non-surgery patients with atrial fibrillation of seven days or less) and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome patients.

Officers and directors

W. James O'Shea Chairman of the Board
William L. Hunter M.D., President, Chief Executive Officer, Director
Age: 51
Jennifer Archibald Chief Financial Officer
Sheila M. Grant Chief Operating Officer
David D. McMasters J.D. General Counsel
Richard M. Glickman L.L.D Lead Independent Director
Age: 57
Mark H. N. Corrigan M.D. Director
Age: 56
Arthur H. Willms Director
Age: 73
Peter W Roberts CPA Independent Director
Harold H. Shlevin M.D., Ph.D Independent Director
Age: 65